Mineralys Therapeutics, Inc., based in the United States, is a pharmaceutical company with a focus on developing medications to target diseases related to high levels of aldosterone. They have a product candidate called lorundrostat, a selective aldosterone synthase inhibitor, for the treatment of uncontrolled hypertension and resistant hypertension. With a risk rating score of 29.0, the company is categorized as having a medium risk level. Mineralys Therapeutics, Inc. is committed to developing sustainable pharmaceutical solutions and maintaining good governance practices.